Showing 4091-4100 of 5331 results for "".
- Fibrocell to Collaborate with Castle Creek Pharmaceuticals to Develop and Commercialize RDEB Gene Therapyhttps://practicaldermatology.com/news/fibrocell-to-collaborate-with-castle-creek-pharmaceuticals-to-develop-and-commercialize-rdeb-gene-therapy/2460004/Fibrocell Science, Inc. has entered into a collaboration agreement with Castle Creek Pharmaceuticals to develop and commercialize Fibrocell’s lead gene therapy candidate, FCX-007, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a rare, life-threatening genetic disord
- L'Oreal To Support Reconstruction of Notre Dame Cathedralhttps://practicaldermatology.com/news/loreal-to-support-reconstruction-of-notre-dame-cathedral/2460003/The Bettencourt Meyers family and the L’Oréal Group are making a joint donation of 100 million euros toward the “renaissance” of the Notre-Dame Cathedral, which they describe as a symbol of French heritage and common history.
- Industry Vet Linda Esposito Named New CFO at Skyn ICELANDhttps://practicaldermatology.com/news/industry-vet-linda-esposito-named-new-cfo-at-skyn-iceland/2460002/Linda Esposito is the new Chief Financial Officer at Skyn ICELAND, a privately held New York-based skin care company. Ms. Esposito will report to Founder and Chief Executive Officer Sarah Kugelman and will oversee all financial aspects of t
- American Skin Association Names Almirall Distinguished Corporate Leaderhttps://practicaldermatology.com/news/american-skin-association-names-almirall-distinguished-corporate-leader/2459997/Almirall took home the Distinguished Corporate Leadership award by the American Skin Associ
- National Psoriasis Foundation Elects New Leaders to Board of Directorshttps://practicaldermatology.com/news/national-psoriasis-foundation-elects-new-leaders-to-board-of-directors/2459993/To recognize their dedication in helping people with psoriasis and psoriatic arthritis as volunteers, members, and donors, the National Psoriasis Foundation (NPF) elected Jerry Bagel MD, MS of East Windsor, NJ, Mike Refermat of San Diego, CA, and Jodi Wood
- AIM at Melanoma Opens Melanoma Tissue Bank in the UShttps://practicaldermatology.com/news/aim-at-melanoma-opens-melanoma-tissue-bank-in-the-us/2459991/AIM at Melanoma celebrated the grand opening of the first branch of the International Melanoma Tissue Bank Consortium (IMTBC) at the University of Pittsburgh Medical Center (UPMC), Hillman Cancer Center. The Pittsburgh site is one of six global locations of the consortium. These six institutions
- Nextech Partners with RxPhoto for Integrated Image Managementhttps://practicaldermatology.com/news/nextech-partners-with-rxphoto-for-integrated-image-management/2459958/Nextech Systems has launched a new partnership with RxPhoto, a collaborative medical imagery solution. This partnership integrates RxPhoto’s patient photograph
- Biofrontera Acquires Cutanea Life Scienceshttps://practicaldermatology.com/news/biofrontera-acquires-cutanea-life-sciences/2459959/Biofrontera Inc., USA entered into an agreement to acquire all shares in Cutanea Life Sciences, Inc., USA through its subsidiary Biofrontera Newderm LLC as the acquirer, with Maruho Co., Ltd., Japan as the seller. Maruho holds approximately 20 percent of Biofrontera AG. Cutanea is a US-based phar
- CoolSculpting and Sonja Morgan Partner to Talk Bikini Denialhttps://practicaldermatology.com/news/coolsculpting-and-sonja-morgan-partner-to-talk-bikini-denial/2459963/Star of Bravo's "The Real Housewives of New York City" Sonja Morgan is opening up about her ‘Bikini Denial’ as part of her partnership with CoolSculpting. Bikini Denial is the feeling that many woman get when realizing that swimsuit season has snuck up on her and
- More Positive Results Seen with Endo's Injectable Cellulite Treatmenthttps://practicaldermatology.com/news/more-positive-results-for-endos-injectable-cellulite-treatment/2459965/Endo International plc’s injectable cellulite treatment collagenase clostridium histolyticum ("CCH") showed a clinically meaningful and statistically significant improvement compared to placebo for all primary and secondary endpoints in a Phase 2